The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has recommended Zynyz (retifanlimab) for the treatment of anal cancer. 

Zynyz, developed by biopharmaceutical company Incyte, has received the EMA’s positive opinion to treat recurrent squamous cell carcinoma of the anal cancer (SCAC) in combination with carboplatin and paclitaxel. 

SCAC is the most common type of anal cancer, accounting for approximately 85% of all anal cancer cases. Globally, the prevalence of SCAC is estimated at around one or two cases per 100,000 people, with a higher incidence in women than in men. 

Results from a clinical trial, published in The Lancet, showed the combination treatment demonstrated a 37% reduction in the risk of progression or death. Patients in the Zynyz and combination group also achieved a median progression-free survival (PFS) of 9.3 months compared to 7.4 months for patients in the placebo combination group. 

“Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International.  

“If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” 

The CHMP opinion is now being reviewed by the European Commission.